May 12, 2020
scPharmaceuticals narrows projected annual loss for 2020 to $36-40M
Remain on track to resubmit FUROSCIX® NDA with the FDA by mid-year 2020 Strong balance sheet with over $75M in…
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
May 12, 2020
Bicycle Therapeutics Announces Publication of BT5528 Mechanism of Action in AACR Journal Molecular Cancer Therapeutics
– BT5528 optimized to have distinct physiochemical and in vivo properties thought to enable more favorable preclinical safety, efficacy profiles…
May 12, 2020
GRYT Health, Bristol Myers Squibb team up to launch COVID advocacy exchange for patient advocates
Industry leaders connecting patient advocacy organizations in virtual approach ROCHESTER, N.Y. & PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #AdvocacyExchange–In light of the COVID-19…
May 12, 2020
Recent Publications Demonstrate the Performance of the GeoMx DSP and Establish New Standards for Spatial Profiling in Discovery & Translational Research
Nature Biotechnology Publishes Comprehensive Description and Validation of the GeoMx Digital Spatial Profiler Using both nCounter & NGS Read Outs…
May 12, 2020
Gamida Cell Announces Positive Topline Data from Phase 3 Clinical Study of Omidubicel in Patients with High-Risk Hematologic Malignancies
— Study met primary endpoint of time to neutrophil engraftment — — Omidubicel represents potential transformative treatment option for patients…
May 11, 2020
Myriad gets FDA approval of myChoice CDx as companion diagnostic for Lynparza
Te U.S. Food and Drug Administration (FDA) approved the myChoice CDx test for use as a companion diagnostic by healthcare professionals to identify certaikn advanced ovarian cancer patients.
May 11, 2020
Novavax gets up to $388M from CEPI for COVID-19 vaccine making
Novavax said Monday that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of NVX-CoV2373, Novavax’ coronavirus vaccine candidate against SARS-CoV-2.
May 11, 2020
Amryt’s Q1 2020 revenue at $44.6M, up from Q1 last year
Amryt has reported $44.6M unaudited Q1 revenues representing 30% for the first quarter ended March 31, 2020. The net loss for the period was $17.0M, compared to 2.8 in the same period last year.
May 11, 2020
Sterling Pharma Solutions in making of potential COVID-19 treatment
Sterling Pharma has announced a partnership with Accord Healthcare to secure the UK supply chain for Hydroxychloroquine (HCQ), a medication currently under investigation for the prevention and treatment of COVID-19.
May 11, 2020
Aimmune Therapeutics reports Q1 2020 Financial Results and Provides Recent Operational Highlights
Continues to be launch ready for PALFORZIATM EU and Swiss regulatory reviews for PALFORZIA remain on schedule Uninterrupted drug supply…